Mostrar el registro sencillo del ítem

dc.contributor.authorSolorzano Puerto, Antonio
dc.contributor.authorGutiérrez Fernández, José 
dc.contributor.authorRomán, Eva
dc.contributor.authorLuna Del Castillo, Juan De Dios 
dc.contributor.authorRoman, Juan
dc.contributor.authorLiébana Ureña, José 
dc.contributor.authorPiédrola Angulo, Gonzalo
dc.date.accessioned2024-04-09T08:17:56Z
dc.date.available2024-04-09T08:17:56Z
dc.date.issued2007-08
dc.identifier.citationSorlozano A, Gutierrez J, Roman E, de Dios Luna J, Roman J, Liebana J, Piedrola G. A comparison of the activity of tigecycline against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae. Diagn Microbiol Infect Dis. 2007 Aug;58(4):487-9.es_ES
dc.identifier.urihttps://hdl.handle.net/10481/90523
dc.description.abstractWe evaluated the activity of several antibiotics against 225 clinical isolates of Staphylococcus aureus and 252 isolates of Streptococcus agalactiae. Only tigecycline, glycopeptides, and linezolid were active against all the isolates of S. aureus, whereas the beta-lactams were also active against S. agalactiae. Tigecycline could be a good alternative to ampicillin in the treatment of group B Streptococcus infections in patients allergic to beta-lactam.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleA comparison of the activity of tigecycline against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiaees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.diagmicrobio.2007.02.009


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional